Trial Profile
A Phase I Open-label Dose-escalation Study to Evaluate the Safety of Intramuscular Injections of PLX-R18 in Subjects With Incomplete Hematopoietic Recovery Following Hematopoietic Cell Transplantation
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 30 Aug 2023
Price :
$35
*
At a glance
- Drugs Avoplacel (Primary)
- Indications Haematological disorders
- Focus Adverse reactions; First in man
- Sponsors Pluri; Pluristem Therapeutics
- 16 Aug 2023 According to Pluri Inc media release, today announced the publication of an article titled Placental expanded mesenchymal-like cells (PLX R18) for poor graft function after hematopoietic cell transplantation A phase I study in the peer reviewed journal Nature Bone Marrow Transplantation.
- 16 Aug 2023 Results presented in a Pluri Inc media release.
- 13 Mar 2023 According to a Pluristem Therapeutics media release, Pluristem Therapeutics has changed its name to Pluri Inc.